Spark Therapeutics, Inc. (ONCE)

[cty]

http://tickerreport.com/banking-finance/426599/spark-therapeutics-receives-new-coverage-from-analysts-at-cowen-and-company-once/



Spark Therapeutics Receives New Coverage from Analysts at Cowen and Company (ONCE)

Posted by Stephan Byrd on Feb 24th, 2015 // No Comments
Share on StockTwits

Spark Therapeutics logoInvestment analysts at Cowen and Company initiated coverage on shares of Spark Therapeutics (NASDAQ:ONCE) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

ONCE has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Spark Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Spark Therapeutics in a research note on Tuesday. They set an “overweight” rating on the stock. Analysts at Rodman & Renshaw initiated coverage on shares of Spark Therapeutics in a research note on Sunday. They set a “buy” rating and a $71.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Spark Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating and a $72.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $71.50.

Spark Therapeutics (NASDAQ:ONCE) opened at 56.68 on Tuesday. Spark Therapeutics has a 52 week low of $40.50 and a 52 week high of $57.24. The stock’s 50-day moving average is $46.85 and its 200-day moving average is $46.85.

Spark Therapeutics, Inc is engaged in the field of gene therapy. The Company develops one-time, life-altering treatments for patients suffering from debilitating genetic diseases. The Company is focused on treating rare diseases where no, or only palliative therapies exist. The Company addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.